Molecular determinants of immunogenic cell death elicited by radiation therapy

被引:16
作者
Galassi, Claudia [1 ]
Klapp, Vanessa [2 ,3 ]
Yamazaki, Takahiro [1 ]
Galluzzi, Lorenzo [1 ,4 ,5 ]
机构
[1] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA
[2] Luxembourg Inst Hlth, Dept Canc Res, Tumor Stroma Interact, Luxembourg, Luxembourg
[3] Univ Luxembourg, Fac Sci Technol & Med, Esch Sur Alzette, Luxembourg
[4] Sandra & Edward Meyer Canc Ctr, New York, NY USA
[5] Caryl & Israel Englander Inst Precis Med, New York, NY USA
关键词
ATP; calreticulin; HMGB1; immune checkpoint inhibitors; PD-L1; type I IFN; CALRETICULIN EXPOSURE; MITOCHONDRIAL-DNA; APOPTOTIC CELLS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; CANCER PROGRESSION; IMMUNE-RESPONSES; DENDRITIC CELLS; POOR-PROGNOSIS; ATP SECRETION;
D O I
10.1111/imr.13271
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune responses against dead cell-associated antigens, provided that (1) said antigens are not perfectly covered by central tolerance (antigenicity), (2) cell death occurs along with the emission of immunostimulatory cytokines and damage-associated molecular patterns (DAMPs) that actively engage immune effector mechanisms (adjuvanticity), and (3) the microenvironment of dying cells is permissive for the initiation of adaptive immunity. Finally, ICD-driven immune responses can only operate and exert cytotoxic effector functions if the microenvironment of target cancer cells enables immune cell infiltration and activity. Multiple forms of radiation, including non-ionizing (ultraviolet) and ionizing radiation, elicit bona fide ICD as they increase both the antigenicity and adjuvanticity of dying cancer cells. Here, we review the molecular determinants of ICD as elicited by radiation as we critically discuss strategies to reinforce the immunogenicity of cancer cells succumbing to clinically available radiation strategies.
引用
收藏
页码:20 / 32
页数:13
相关论文
共 222 条
  • [1] The adenosine pathway in immuno-oncology
    Allard, Bertrand
    Allard, David
    Buisseret, Laurence
    Stagg, John
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (10) : 611 - 629
  • [2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [3] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [4] Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy
    Bai, Peng
    Li, Yongzheng
    Zhou, Qiuping
    Xia, Jiaqi
    Wei, Peng-Cheng
    Deng, Hexiang
    Wu, Min
    Chan, Sanny K.
    Kappler, John W.
    Zhou, Yu
    Tran, Eric
    Marrack, Philippa
    Yin, Lei
    [J]. ONCOIMMUNOLOGY, 2021, 10 (01):
  • [5] Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
    Bains, Simer J.
    Abrahamsson, Hanna
    Flatmark, Kjersti
    Dueland, Svein
    Hole, Knut H.
    Seierstad, Therese
    Redalen, Kathrine Roe
    Meltzer, Sebastian
    Ree, Anne Hansen
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (03) : 355 - 364
  • [6] The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
    Barker, Holly E.
    Paget, James T. E.
    Khan, Aadil A.
    Harrington, Kevin J.
    [J]. NATURE REVIEWS CANCER, 2015, 15 (07) : 409 - 425
  • [7] Therapeutic targeting of tumour myeloid cells
    Barry, Simon T.
    Gabrilovich, Dmitry I.
    Sansom, Owen J.
    Campbell, Andrew D.
    Morton, Jennifer P.
    [J]. NATURE REVIEWS CANCER, 2023, 23 (04) : 216 - 237
  • [8] Bates JE, 2021, INT J RADIAT ONCOL, V111, pE351, DOI 10.1016/j.ijrobp.2021.07.1054
  • [9] Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
    Benci, Joseph L.
    Xu, Bihui
    Qiu, Yu
    Wu, Tony J.
    Dada, Hannah
    Twyman-Saint Victor, Christina
    Cucolo, Lisa
    Lee, David S. M.
    Pauken, Kristen E.
    Huang, Alexander C.
    Gangadhar, Tara C.
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    Feldman, Michael D.
    Ishwaran, Hemant
    Vonderheide, Robert H.
    Maity, Amit
    Wherry, E. John
    Minn, Andy J.
    [J]. CELL, 2016, 167 (06) : 1540 - +
  • [10] Natural killer cells in antiviral immunity
    Bjorkstrom, Niklas K.
    Strunz, Benedikt
    Ljunggren, Hans-Gustaf
    [J]. NATURE REVIEWS IMMUNOLOGY, 2022, 22 (02) : 112 - 123